DAVOS LIFE SCIENCE PTE. LTD.

Business Description

DAVOS LIFE SCIENCE PTE. LTD. is registered as a business entity on 09 December 2004 (20.1 years ago) structured as a Private Company Limited By Shares (Local Company) with 4 officer(s) in-charge. The business jurisdiction is overseen by the Accounting and Corporate Regulatory Authority (ACRA), a government agency from Singapore with the given Business Registration Number / Unique Entity Number (UEN) 200415927E. The business official address is located at 3 Biopolis Drive #04-19, Synapse, Singapore 138623 with main trading activity as Sales Of Pharmaceutical & Bio-pharmaceutical Intermediates & Fine Chemicals in the primary industry of 46649: Wholesale Of Chemicals And Chemical Products N.e.c. using Singapore Dollars - SGD as its default trading currency. The business name remains unchanged since inception. The business annual account filing date falls on 30 April and is currently operational with the status of 'Live Company'. The business paid up share capital is SGD NaN, with preference share capital of SGD NaN, and other share capital at SGD NaN.

In the past 365 days, DAVOS LIFE SCIENCE PTE. LTD. has received a total of Login to view reported payment review(s). 19 were rated Good and Login to view were rated Poor. The latest review was made on 2023-07-12 and it was reported "Good". The aggregated good payment amount is equivalent to USD 15,067, and aggregated poor payment amount is equivalent to USD Login to view. Its current payment rating of "A" suggest a healthy payment culture where settlement with stakeholders is always prioritised. Since the business is currently active, it also signals positive financial standing. The appointment of FIDUCIA LLP as auditor indicates that the business is medium to large sized as it is required to meet additional regulatory requirements either due to reported revenue or assets exceeding SGD 10 million or has more than 50 employees in the previous two fiscal years.

DAVOS LIFE SCIENCE PTE. LTD. is not yet a Prompt Payment Initiative Signatory.

Last updated on 30 April 2023